Skip to Content
 
Emily  Chan

Emily Chan, M.D., Ph.D.

Associate Professor of Medicine (Hematology/Oncology)
Medical Oncologist

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-8580
  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    2220 Pierce Avenue
    777 Preston Research Building
    Nashville, TN 37232-6307
Profile

Dr. Chan joined the faculty of the Vanderbilt-Ingram Cancer Center after finishing her Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center. During her fellowship, her research focus was on the manipulation of an enzyme in the apoptotic pathway to affect tumor growth and radiation sensitivity, and her clinical focus was on gastrointestinal malignancies. At Vanderbilt, her clinical interest is in gastrointestinal malignancies, including cancers of the colon, rectum, anal canal, esophagus, stomach, small intestine, gallbladder, pancreas, liver, and bile duct. Her research interests reside in the development of more effective treatment regimens for these diseases, particularly colorectal cancer, and the identification of markers that may predict response to specific therapies.

Research Description

At Vanderbilt, Dr. Chan's clinical interest is in gastrointestinal malignancies, including cancers of the colon, rectum, anal canal, esophagus, stomach, small intestine, gallbladder, pancreas, liver, and bile duct. Her research interests reside in the development of more effective treatment regimens for these diseases, particularly colorectal cancer, and the identification of markers that may predict response to specific therapies.

Publications
  • Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet. Genomics. 2016 Mar; 26(3): 133-7. PMID: 26658227, PMCID: PMC4738010, DOI: 10.1097/FPC.0000000000000197, ISSN: 1744-6880.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26658227.
  • Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist [print-electronic]. 2016 Jan 1/19/2016; PMID: 26786262, PII: theoncologist.2015-0319, DOI: 10.1634/theoncologist.2015-0319, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26786262.
  • Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, AndrĂ© T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin. Cancer Res [print-electronic]. 2015 Dec 12/15/2015; 21(24): 5469-79. PMID: 26341920, PII: 1078-0432.CCR-15-0526, DOI: 10.1158/1078-0432.CCR-15-0526, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26341920.
  • Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J. Clin. Oncol [print-electronic]. 2015 Dec 12/1/2015; 33(34): 4032-8. PMID: 26460303, PMCID: PMC4669589, PII: JCO.2015.63.2497, DOI: 10.1200/JCO.2015.63.2497, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26460303.
  • Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, Thomas CR, Chan E, Cataldo PA, Marcet JE, Medich DS, Johnson CS, Oommen SC, Wolff BG, Pigazzi A, McNevin SM, Pons RK, Bleday R. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol [print-electronic]. 2015 Nov; 16(15): 1537-46. PMID: 26474521, PII: S1470-2045(15)00215-6, DOI: 10.1016/S1470-2045(15)00215-6, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26474521.
  • Chan E, Berlin J. Biliary tract cancers: understudied and poorly understood. J. Clin. Oncol [print-electronic]. 2015 Jun 6/1/2015; 33(16): 1845-8. PMID: 25918294, PII: JCO.2014.59.7591, DOI: 10.1200/JCO.2014.59.7591, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25918294.
  • Chan E, Kwak EL, Hwang J, Heiskala M, de La Bourdonnaye G, Mita M. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease. Cancer Chemother. Pharmacol [print-electronic]. 2015 Apr; 75(4): 701-9. PMID: 25627002, DOI: 10.1007/s00280-015-2682-2, ISSN: 1432-0843.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25627002.
  • Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25212606.
  • Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine. 2015; 10: 1201-9. PMID: 25709442, PMCID: PMC4334335, PII: ijn-10-1201, DOI: 10.2147/IJN.S62911, ISSN: 1178-2013.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25709442.
  • Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, . Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J. Natl. Cancer Inst [electronic-print]. 2014 Jul; 106(7): PMID: 24925349, PMCID: PMC4110470, PII: dju106, DOI: 10.1093/jnci/dju106, ISSN: 1460-2105.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24925349.
  • Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med [print-electronic]. 2014 Jun; 3(3): 572-9. PMID: 24574334, PMCID: PMC4101748, DOI: 10.1002/cam4.208, ISSN: 2045-7634.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24574334.
  • Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, . Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer [print-electronic]. 2014 Jun; 13(2): 100-9. PMID: 24512953, PMCID: PMC4019685, PII: S1533-0028(13)00129-1, DOI: 10.1016/j.clcc.2013.12.002, ISSN: 1938-0674.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24512953.
  • Chan E, Berlin J. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children [editorial]. J. Clin. Oncol [print-electronic]. 2014 Feb 2/20/2014; 32(6): 487-8. PMID: 24419124, PII: JCO.2013.53.5617, DOI: 10.1200/JCO.2013.53.5617, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24419124.
  • Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25232828.
  • Ciombor KK, Berlin J, Chan E. Aflibercept. Clin. Cancer Res [print-electronic]. 2013 Apr 4/15/2013; 19(8): 1920-5. PMID: 23444216, PMCID: PMC3710732, PII: 1078-0432.CCR-12-2911, DOI: 10.1158/1078-0432.CCR-12-2911, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23444216.
  • Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23436834.
  • Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw. 2012 Dec 12/1/2012; 10(12): 1567-72. PMID: 23221791, PII: 10/12/1567, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23221791.
  • Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am. J. Clin. Oncol. 2011 Dec; 34(6): 581-6. PMID: 21217396, PMCID: PMC3133812, DOI: 10.1097/COC.0b013e3181fe46a1, ISSN: 1537-453X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21217396.
  • Chan E. Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer. Clin Adv Hematol Oncol. 2010 Jan; 8(1): 37-9. PMID: 20351681, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20351681.
  • Chan E, Kachnic LA, Thomas CR. Anal cancer: progress on combined-modality and organ preservation. Curr Probl Cancer. 2009 Sep; 33(5): 302-26. PMID: 20082844, PII: S0147-0272(09)00048-8, DOI: 10.1016/j.currproblcancer.2009.10.003, ISSN: 1535-6345.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20082844.
  • Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am. J. Clin. Oncol. 2008 Oct; 31(5): 413-6. PMID: 18838875, PII: 00000421-200810000-00002, DOI: 10.1097/COC.0b013e318168ef2a, ISSN: 1537-453X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18838875.
  • Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs [print-electronic]. 2008 Aug; 26(4): 339-45. PMID: 18463792, DOI: 10.1007/s10637-008-9133-4, ISSN: 0167-6997.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18463792.
  • Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs [print-electronic]. 2008 Jun; 26(3): 241-7. PMID: 18217204, DOI: 10.1007/s10637-008-9118-3, ISSN: 0167-6997.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18217204.
  • Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008 Mar 3/13/2008; 358(11): 1109-17. PMID: 18337601, PMCID: PMC2361129, PII: 358/11/1109, DOI: 10.1056/NEJMoa074943, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18337601.
  • Chan E, Berlin JD. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will?. Gastrointest Cancer Res. 2007 Sep; 1(5): 204-6. PMID: 19262710, PMCID: PMC2632532, ISSN: 1934-7820.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19262710.